Abstract
Purpose
Methods
Findings
Implications
Key words
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical TherapeuticsReferences
Diabetes fact sheet. World Health Organization website. http://www.who.int/mediacentre/factsheets/fs312/en/. Accessed November 26, 2014.
Statistics about diabetes. American Diabetes Association website. http://www.diabetes.org/diabetes-basics/statistics/?loc=db-slabnav. Accessed November 26, 2014.
Heart disease. American Diabetes Association website. http://www.diabetes.org/living-with-diabetes/complications/heart-disease/. Accessed November 26, 2014.
- The effect of intensive treatment of diabetes on the development of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group.N Engl J Med. 1993; 329: 977-986
- 10-year follow-up of intensive glucose control in type 2 diabetes.N Engl J Med. 2008; 359: 1577-1589
- Approaches to glycemic treatment.Diabetes Care. 2015; 38: S41-S48
- The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988–2010.Diabetes Care. 2013; 36: 2271-2279
Invokana [package insert]. Janssen Pharmaceuticals, Inc. http://www.invokanahcp.com/prescribing-information.pdf. Accessed November 19, 2014.
Farxiga [package insert]. Bristol-Myers Squibb Company. http://www.azpicentral.com/farxiga/pi_farxiga.pdf#page=1. Accessed November 19, 2014.
Jardiance [package insert]. Boehringer Ingelheim Pharmaceuticals, Inc. http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Jardiance/jardiance.pdf. Accessed November 19, 2014.
- Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications.Diabet Med. 2010; 27: 136-142
- Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus.Drugs. 2010; 70: 377-385
- Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors.Diabetes Obes Metab. 2012; 14: 83-90
- Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study.Diabetes Care. 2013; 36: 2154-2161
- SGLT2 inhibitors in the treatment of type 2 diabetes.Diabetes Res Clin Pract. 2014; 104: 297-322
- Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects.Diabetes Obes Metab. 2011; 13: 47-54
- Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial.Diabetes Obes Metab. 2011; 13: 928-938
- Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT2) inhibitor, and metformin following co-administration in healthy volunteers.Int J Clin Pharmacol Ther. 2013; 51: 132-140
- Pharmacokinetics of empagliflozin, a sodium glucose 2 cotransporter-2 inhibitor, and glimepiride following co-administration in healthy volunteers: a randomized, open-label, crossover study.Diab Res Clin Metab. 2012; 1: 1-7
- Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT2) inhibitor, coadministered with sitagliptin in healthy volunteers.Adv Ther. 2012; 29: 889-899
- A randomized, open-label crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers.Clin Ther. 2013; 35: A33-A42
- Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin.Adv Ther. 2012; 29: 163-177
- Lack of drug-drug interactions between empagliflozin, a sodium glucose cotransporter-2 inhibitor, and warfarin in healthy volunteers.Diabetes Obes Metab. 2013; 15: 316-323
- Pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, and simvastatin following co-administration in healthy volunteers.Int J Clin Pharmacol Ther. 2014; 52: 973-980
- Lack of clinically relevant drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and verapamil, ramipril, or digoxin in healthy volunteers.Clin Ther. 2013; 35: 226-235
- Effects of hydrochlorothiazide on the pharmacokinetics, pharmacodynamics, and tolerability of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants.Clin Ther. 2014; 36: 698-710
- Assessing pharmacokinetic interactions between the sodium glucose cotransporter 2 inhibitor empagliflozin and hydrochlorothiazide or torasemide in patients with type 2 diabetes mellitus: a randomized, open-label, crossover study.Clin Ther. 2015; ([Epub ahead of print])
- Effects of rifampin and mefenamic acid on the pharmacokinetics and pharmacodynamics of dapagliflozin.Diabetes Obes Metab. 2013; 15: 280-283
- Drug-drug interactions with sodium-glucose cotransporters type 2 (SGLT2) inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes mellitus.Clin Pharmacokinet. 2014; 53: 295-304
- Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus.J Clin Pharmacol. 2013; 53: 601-610
- Effect of empagliflozin on the steady-state pharmacokinetics of ethinylestradiol and levonorgestrel in healthy female volunteers.Clin Drug Investig. 2013; 20: 351-357
- Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR).Curr Med Res Opin. 2014; 30: 1759-1768
- Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise.Diabetes Obes Metab. 2013; 15: 372-382
- Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study.Curr Med Res Opin. 2014; 30: 163-175
- Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomized trial.Diabetologia. 2013; 56: 2582-2592
- Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial.Lancet. 2013; 382: 941-950
- Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial.Int J Clin Pract. 2013; 67: 1267-1282
- Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial.Diabetes Care. 2013; 36: 2508-2515
- Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.Diabetes Obes Metab. 2014; 16: 467-477
- Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial.Diabetes Care. 2010; 33: 2214-2224
- Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise.Diabetes Obes Metab. 2014; 16: 1102-1110
- Dapagliflozin monotherapy in drug-naïve patients with diabetes: a randomized-controlled trial of low-dose range.Diabetes Obes Metab. 2012; 14: 951-959
- Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial.Diabetes Care. 2011; 34: 2015-2022
- Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomized, double-blind, placebo controlled trial.Lancet. 2010; 375: 2223-2233
- Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy.Diabetes Care. 2012; 35: 1473-1478
- Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.Diabetes Care. 2014; 37: 740-750
- Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial.Ann Intern Med. 2012; 156: 405-415
- Pharmacokinetics, pharmacodynamics, safety and tolerability of 4 weeks’ treatment with empagliflozin in Japanese patients with type 2 diabetes mellitus.J Diabetes Investig. 2013; 4: 613-617
- A phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes.Diabetes Obes Metab. 2013; 15: 721-728
- Empagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, 12-week, double-blind, placebo-controlled, phase II trial.Adv Ther. 2014; 31: 621-638
- Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycemia.Diabetes Obes Metab. 2013; 15: 1154-1160
- Empagliflozin as add-on to metformin plus sulfonyl - urea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial.Diabetes Care. 2013; 36: 3396-3404
- Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial.Diabetes Obes Metab. 2014; 16: 147-158
- Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes.Diabetes Care. 2014; 37: 1815-1823
- Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes.Diabetes Care. 2013; 36: 4015-4021
Fulcher G, Matthews DR, Perkovic V, et al. Canagliflozin (CANA) in subjects with type 2 diabetes mellitus (T2DM) inadequately controlled on sulfonylurea (SU) monotherapy: a CANVAS study. Abstract presented at 73rd Annual American Diabetes Association Scientific Sessions; June 21–25, 2013; Chicago, Ill. Abstract No. 1124-P.
- Efficacy and safety of canagliflozin (CANA), an inhibitor of sodium glucose co-transporter 2 (SGLT2), added-on to insulin therapy +/− oral agents in type 2 diabetes [abstract 764].Diabetologia. 2012; 55: S314
- SGLT inhibitors in management of diabetes.Lancet Diabetes Endocrinol. 2013; 1: 140-151
- Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis.Ann Int Med. 2013; 59: 262-274
- Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors.J Am Soc Hypertens. 2014; 8: 330-339
- SGLT-2 inhibitors and their potential in the treatment of diabetes.Diabetes Metab Syndr Obes. 2013; 6: 453-467
- Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial.Am Heart J. 2013; 166: 217-223
F.D.A. Briefing Document (NDA 204042) Invokana (canagliflozin) tablets. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM334550.pdf. Accessed December 5, 2014.
- Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.Diabetes Metab Res Rev. 2014; 30: 204-221
F.D.A. Briefing Document (NDA 202293) Dapagliflozin oral tablets, 5 and 10 mg. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM378076.pdf. Accessed December 4, 2014.
- Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOMETM).Cardiovasc Diabetol. 2014; 13: 102
- Canagliflozin, a new sodium-glucose cotransporter 2 inhibitor, in the treatment of diabetes.Am J Health Syst Pharm. 2013; 70: 311-319
Meta-analysis in post-marketing surveillances for SGLT2 inhibitors in patients with type 2 diabetes mellitus. ClinicalTrials.gov website. https://clinicaltrials.gov/ct2/show/NCT02284269?term=empagliflozin+and+cancer&rank=1. Accessed January 27, 2015.
- AACE comprehensive diabetes management algorithm 2013.Endocr Pract. 2013; 19: 327-336